The director of mental healthcare for the Department of Veterans Affairs said that she believes research on psychedelic assisted therapy should be more like real-world scenarios. She said that requiring subjects to be diagnosed and to pass strict screening protocols makes it impossible to generalize accurately the effects of this treatment.
Rachel Yehuda is a professor in psychiatry, neurobiology and chairs the psychiatry section at Mount Sinai’s Icahn school of medicine. “However, it has been disheartening for me to see how many people are excluded based on medical and psychological exclusions.”
Yehuda said, “We may be being overly conservative, but psychedelics still carry the stigma of being Schedule I compounds and potentially dangerous.” “But when we discuss, for instance, people of colour not being represented, I was sure that we would solve this problem.”
Yehuda noted that in her own research, conducted at a VA hospital in New York, about one-third of the patients were white. Many people of color are excluded from psychedelic research because they have comorbidities that are more prevalent in vulnerable populations. She said that “we have many, many Latinas and African Americans” but because of health inequities many of them are screened out.
Yehuda spoke as part of a session on “practical aspects of psychedelics” at the HHS Workshop, “Exploring Ethical and practical Considerations of Psychedelics Research”, hosted by the Department’s Office of Human Research Protections. sessions also focused on the ethics and laws surrounding psychedelics as well as ways to protect public trust and avoid a “psychedelics Bubble.”
Yehuda asked during the discussion, “I wonder if we’re designing our trials so they are welcoming to everyone we want to study in order to generalize our results.” She said, “I get emails from people who are desperate to tell me their story all the time.” “By reading the second paragraph I can tell that we won’t be taking complex cases or those with comorbidities. “I think it’s an ethics issue.”
Browser does not support the iframe
Yehuda discussed the challenges of blind studies in which participants, and sometimes researchers, were supposed to be unaware of whether a treatment was experimental or a placebo. Yehuda explained that in the psychedelic space, it can be challenging to create placebos because these substances produce an experience. She also noted that most research on psychotherapy techniques is not designed to be blind. She asked, “What are we trying control in studies using active placebos?”
She pointed out that, unlike some pharmaceutical trials of psychedelics, the research has usually paired a psychedelic experience with a more traditional form of therapy, like talk therapy. “Nobody has done a study where they just give a psychedelic, and then say, ‘See you!’ They’re not doing adequate preparation, support, or integration,” Yehuda stated.
She said that initially, Yehuda was sceptical about psychedelics being used as a treatment for mental illness. She is now more interested in “what makes people respond or not respond?”
“Another better question – and this is a research we are about to do – is a dose optimization, Yehuda said, “which asks: ‘Is it that you’re just not a responder or did you not receive enough therapy? ‘”
R. A second official of the government– Cameron Wolf, a senior advisor for the Substance Abuse and Mental Health Services Administration’s (SAMHSA) Center for Substance Abuse Protection and the Office of Prevention Innovation–moderated the conference’s third session, which focused on safeguarding public trust in psychedelics and preventing what organizers called “another psychedelics bubble.”
Wolf asked the panelists questions, but he also noticed some similarities between today’s psychedelics and HIV in the 1980s & 1990s.
Wolf noted that “some parallels” exist between his work on psychedelics and his career, which has focused on HIV prevention, treatment and care programs, both nationally and internationally.
He said, “There was such desperation.” “So many people on the verge of death were looking for answers, treatments, life-saving options and were willing to do anything, regardless of safety.”
Wolf noted that once more effective drugs became available in the mid-1990s the main issue was access. “Even when, in 1996, we had effective combination treatments with protease inhibitors coming out that literally brought people back from the dead,” he explained, “still issues about access and equity–and then how to tailor and target programs towards those most vulnerable–continued.”
Wolf concluded by saying, “This is only the beginning.”
Researchers published Phase 3 findings in the journal Nature during the same week as the event. They showed that treatment with MDMA reduced symptoms for patients with moderate to severe PTSD. Researchers published Phase 3 results in Nature the same week of the event showing that treatments with MDMA reduced symptoms among patients with moderate-to-severe PTSD. The FDA could consider MDMA as early as next year, based on the findings.
Separate research published last week found that the use psilocybin is linked to “persistent reductions” of depression, anxiety and alcohol abuse, as well as an increase in emotional regulation, spiritual wellness, and extraversion.
This was a separate report from the American Medical Association that showed people with major depressive disorder experienced “clinically meaningful sustained reductions” in their symptoms even after taking just one dose.
A study published in the last month showed that administered a small amount of MDMA with psilocybin or LSD , appears to reduce uncomfortable feelings like guilt or fear which are sometimes side effects when consuming magic mushrooms or LSD.
The first of its kind analysis, released in June, provided novel insights into how psychedelic assisted therapy seems to help people struggling against alcoholism.
The National Institute on Drug Abuse at the federal level has recently begun soliciting proposals to support a series research initiatives that aim to investigate how psychedelics can be used to treat addiction.
House Committee Clears Psychedelics and Marijuana Pharmaceutical Labeling Amendements for Floor Votes
Photo elements are courtesy of carlosemmaskype, and Apollo.
The original post Federal Officials Discuss Psychedelics at Workshop Hosted by Top Health Agency first appeared on Marijuana Moment.
